Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mardi, octobre 27
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Outlook Therapeutics Inc
OTLK
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$0.5133
-0.006
-1.16%
Dern. MÀJ: Oct 26, 7:42 PM
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Outlook Therapeutics Financials
Outlook Therapeutics (OTLK) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Outlook Therapeutics Q3 Adj. EPS $(0.09), Inline, Sales $9.000K Miss $5.300M Estimate
Outlook Therapeutics (NASDAQ:OTLK) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 79.55 percent increase over losses of $(0.44) per share from the same period last
Benzinga Newsdesk
S&P 500 Hits New Record High Following PPI Data: Investor Sentiment Improves, Fear Index Remains In ‘Greed’ Zone
CNN Fear & Greed index showed improved market sentiment, with S&P 500 hitting a new record high after PPI data release. Nasdaq up 0.81%.
Avi Kapoor
Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Outlook Therapeutics (NASDAQ: OTLK) to release Q3 earnings on Aug. 14. Analysts expect a loss of 8 cents/share. Analysts rate it Neutral or Buy.
Avi Kapoor
PRO
Outlook Therapeutics Q2 Adj. EPS $(0.16) Misses $(0.12) Estimate, Sales $128.000K Miss $4.400M Estimate
Outlook Therapeutics (NASDAQ:OTLK) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.12) by 33.33 percent. This is a 60 percent increase over losses of $(0.40) per share
Benzinga Newsdesk
Outlook Therapeutics Earnings Report: Q1 Overview
Benzinga Insights
PRO
Outlook Therapeutics Q1 Adj. EPS $(0.22) Misses $(0.18) Estimate, Sales $(1.208M) Miss $5.025M Estimate
Outlook Therapeutics (NASDAQ:OTLK) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.18) by 22.22 percent. This is a 75.28 percent increase over losses of $(0.89) per share
Benzinga Newsdesk
